Dominique Hussey comments in Bloomberg BNA on draft changes to Canada's patent litigation process for prescription drugs. She points out that the changes create new opportunities and challenges, introduce complexity into the litigation and will raise new procedural and substantive issues that have no precedent. The amendments could take effect as early as September 21, 2017, when the Comprehensive Economic Trade Agreement (CETA) that inspired the changes will be provisionally applied.
In The News
Dominique Hussey in Bloomberg on Canada's Pharmaceutical IP Rules
July 26, 2017
Republishing Requests
For permission to republish this or any other publication, contact Amrita Kochhar at kochhara@bennettjones.com.
For informational purposes only
This publication provides an overview of legal trends and updates for informational purposes only. For personalized legal advice, please contact the authors.
Author
Chief Executive Officer
From the Same Authors
See AllAnnouncement
Dominique T. Hussey, Melanie Teetaert & Cheryl M. Woodin
Dominique Hussey, Melanie Teetaert and Cheryl Woodin Recognized in Benchmark's Top 100 Women in Litigation
August 14, 2025Announcement
& 15 more
Eighteen Bennett Jones Lawyers Ranked in Lexpert's Special Edition on Health Sciences
July 2, 2025Announcement
& 30 more
Bennett Jones Lawyers Named Among Canada's Top Litigators By Benchmark Canada
May 1, 2025Latest Insights
See All Insights
Blog
Luke Morrison, Ashley M. White & Pamela Clark
Wind In The Sails of Canadian Energy Project Development: Major Projects Office Open For Business, and Details of Fast-Tracked Projects Emerging
September 18, 2025
Blog
& 2 more
Sinclair v. Venezia Turismo: The SCC Clarifies Approach to Jurisdiction Against Multiple Defendants in Cross-Border Disputes
September 18, 2025
Blog
Lorelei Graham
Fast Tracks and Green Gaps Part IV: Shifting Gears: How the United States' Exit from Climate Protection Fuels Canada's IP Advantage
September 17, 2025